“肝”问路在何方--肝癌免疫检查点抑制剂疗效预测指标的探索
PD-L1
TMB/MSI
Wnt/β-catenin信号通路
Figure 2.Kaplan-Meier PFS on IO and sorafenib therapy for patients with WNT-activatedtumors.
1. Pinter, M., Jain, R. K. & Duda, D.G. The Current Landscape of Immune Checkpoint Blockade in HepatocellularCarcinoma: A Review. JAMA Oncology (2020)doi:10.1001/jamaoncol.2020.3381.
2. Champiat, S. etal. Hyperprogressive disease: recognizing a novel pattern to improvepatient management. Nature Reviews Clinical Oncology vol. 15 748–762(2018).
3. Scheiner, B. etal. Programmed cell death protein-1 (PD-1)-targeted immunotherapy inadvanced hepatocellular carcinoma: efficacy and safety data from an internationalmulticentre real-world cohort. Aliment. Pharmacol. Ther. 49,1323–1333 (2019).
4. El-Khoueiry,A. B. et al. Nivolumab in patients with advanced hepatocellularcarcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 doseescalation and expansion trial. Lancet 389, 2492–2502 (2017).
5. Sangro, B. etal. LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survivaloutcomes with nivolumab versus sorafenib as first-line treatment in patientswith advanced hepatocellular carcinoma. Ann. Oncol. 31, S241–S242(2020).
6. Zhu, A. X. etal. Pembrolizumab in patients with advanced hepatocellular carcinomapreviously treated with sorafenib (KEYNOTE-224): a non-randomised, open-labelphase 2 trial. Lancet Oncol. 19, 940–952 (2018).
7. Bonneville, R.et al. Landscape of Microsatellite Instability Across 39 Cancer Types. JCOPrecis. Oncol. 1–15 (2017) doi:10.1200/po.17.00073.
8. Ang, C. etal. Prevalence of established and emerging biomarkers of immune checkpointinhibitor response in advanced hepatocellular carcinoma. Oncotarget 10,4018–4025 (2019).
9. Harding, J. J.et al. Prospective genotyping of hepatocellular carcinoma: Clinicalimplications of next-generation sequencing for matching patients to targetedand immune therapies. Clin. Cancer Res. 25, 2116–2126 (2019).
10. Havel, J. J.,Chowell, D. & Chan, T. A. The evolving landscape of biomarkers forcheckpoint inhibitor immunotherapy. Nature Reviews Cancer (2019)doi:10.1038/s41568-019-0116-x.
精彩推荐:
- End -